Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Wednesday 03 February, 2021

Sensyne Health PLC

Launch of AI algorithm for patient management

RNS Number : 7884N
Sensyne Health PLC
03 February 2021

Sensyne Health announces the launch of its first operational AI algorithm for real-time hospital management of patients


SYNE-OPS-1 runs on the Company's SENSE AI algorithm engine and provides real-time operational decision-making support to NHS managers coping with the pressures on resources caused by COVID


Co-developed with Chelsea and Westminster Hospital NHS Foundation Trust and now used by the Trust to help manage ICU resources during the pandemic


New SYNE-OPS-1 product is the first in a series of operational AI algorithms to be launched commercially and offered across the UK and US health systems


Oxford, U.K. 03 February 2021:   Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces the launch of SYNE-OPS-1, the first operational AI algorithm developed on its SENSE algorithm engine, a cloud-based platform to support real-time operational and clinical patient management across multiple medical conditions.

SYNE-OPS-1 provides an hourly risk forecast of the expected number of future ICU admissions and the future demand for ventilators, based upon an analysis of clinical data on COVID patients being admitted to hospital. This enables hospital managers to direct resources across the hospital more effectively in the face of changing numbers of patient admissions amid the pandemic.

The algorithm uses anonymised clinical data on patients with COVID such as vital signs and laboratory test results transmitted to the SENSE clinical AI platform. These data are then analysed and the results presented via a dashboard to help hospital managers make informed decisions about the need for hospital resources.

SYNE-OPS-1 is now integrated into the operational workflow at Chelsea and Westminster Hospital NHS Foundation Trust to help the Trust predict ICU capacity needs for patients with COVID.

SYNE-OPS-1 is the first in a number of operational algorithms expected to be developed by Sensyne using the SENSE platform.  SYNE-OPS-1 is now being marketed to other hospitals in the UK and USA .

Roger Chinn, Chief Medical Officer and Chief Clinical Information Officer at Chelsea & Westminster Hospital NHS Foundation Trust  said : "The SYNE-OPS-1 algorithm has proved invaluable during this current wave of the pandemic. We are able to predict ventilator and non-mechanical support requirements in ICU, helping us to make best use of our expertise and resources. In collaboration with Sensyne Health and as part of our CW Innovation programme, we are embracing digital innovation, data integration, and analytics to support and improve clinical decision making and practice."

Lord (Paul) Drayson PhD FREng CEO said: "The successful deployment of our first operational algorithm, developed in collaboration with our research partners at Chelsea and Westminster NHS Foundation Trust, is an important milestone for Sensyne. We aim to build a broad range of operational algorithms on our SENSE platform to help significantly improve the performance of health systems with the potential of generating a significant commercial return for Sensyne and our research partners."





For more information please contact:

Sensyne Health ( )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Michael Norris, Interim Chief Financial Officer


Dr Richard Pye, Chief Investment Officer

Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

Sukaina Virji

Davide Salvi

[email protected]


About Sensyne Health  


Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).


For more information, please visit:

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t